Q-omics provides the consensus-scored STMN4 profile across patient tissues and cancer cell-line models. STMN4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, STMN4 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, STMN4 RNA expression shows 12,364 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCEC, COAD, and ACC as cancer lineages where STMN4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STMN4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STMN4 survival associations across molecular data types. STMN4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STMN4 RNA expression–survival associations across cancer types. High STMN4 expression shows unfavorable associations in UCEC, ACC, UVM, MESO and KICH, but favorable associations in SKCM. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for STMN4 RNA expression.
This table summarizes STMN4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for STMN4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STMN4 shows lower tumor expression in COAD, READ, STAD, KICH and UCEC and higher tumor expression in HNSC. The COAD box plot shows higher STMN4 RNA expression in normal versus tumor tissue (log2 FC = −0.963, t-test p < 0.001).
This table shows molecular features associated with STMN4 in patient tissues and cancer cell lines. In patient samples, STMN4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, STMN4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LUNG_SCLC.
